Oral valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic stem cell transplantation recipients

被引：0
|
作者：
Pastore, D. [1 ]
Carluccio, P. [1 ]
Gaudio, F. [1 ]
Perrone, T. [1 ]
Delia, M. [1 ]
Albano, F. [1 ]
Manduzio, P. [1 ]
Fesce, V. [1 ]
Mongelli, P. [1 ]
Liso, V. [1 ]
Specchia, G. [1 ]
机构：
[1] Univ Bari, Bari, Italy
来源：
BONE MARROW TRANSPLANTATION | 2008年 / 41卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S266 / S267
页数：2
相关论文
共 50 条
  • [41] Cytomegalovirus viral load at initiation of pre-emptive antiviral therapy impacts cytomegalovirus dynamics in pediatric allogeneic hematopoietic cell transplantation recipients
    Gutierrez, Valentina
    Stanek, Joseph
    Ardura, Monica I.
    Song, Eunkyung
    TRANSPLANT INFECTIOUS DISEASE, 2024,
  • [42] EFFICACY AND SAFETY PROFILE OF FOSCARNET AS PRE-EMPTIVE THERAPY FOR CYTOMEGALOVIRUS INFECTION IN HEMATOPOIETIC STEM CELL TRANSPANT RECIPIENTS
    Metafuni, E.
    Chiusolo, P.
    Sica, S.
    Sora, F.
    Laurenti, L.
    Giammarco, S.
    Bregante, S.
    Van Lint, M. T.
    Dominietto, A.
    Angelucci, E.
    Bacigalupo, A.
    HAEMATOLOGICA, 2017, 102 : 146 - 147
  • [43] Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation
    Devyatko, E
    Zuckermann, A
    Ruzicka, M
    Bohdjalian, A
    Wieselthaler, G
    Rödler, S
    Wolner, E
    Grimm, M
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2004, 23 (11): : 1277 - 1282
  • [44] Management of human cytomegalovirus infection in transplant recipients by the pre-emptive therapy approach
    Gerna, Giuseppe
    Baldanti, Fausto
    Lilleri, Daniele
    FUTURE VIROLOGY, 2009, 4 (02) : 155 - 164
  • [45] Improving Safety of Preemptive Therapy with Oral Valganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation
    Barkam, Corinna
    Kamal, Haytham
    Dammann, Elke
    Diedrich, Helmut
    Buchholz, Stefanie
    Eder, Matthias
    Krauter, Juergen
    Ganser, Arnold
    Stadler, Michael
    BONE MARROW RESEARCH, 2012,
  • [46] Evaluation of efficacy and long-term safety of pre-emptive therapy with or without oral valganciclovir for CMV reactivation after allogeneic haematopoetic stem cell transplantation
    Stadler, M.
    Barkam, C.
    Dammann, E.
    Hoy, L.
    Buchholz, S.
    Hertenstein, B.
    Krauter, J.
    Eder, M.
    Ganser, A.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S162 - S162
  • [47] LOW DOSE VALGANCICLOVIR AS A PRE-EMPTIVE THERAPY IS EFFECTIVE FOR CYTOMEGALOVIRUS INFECTION IN KIDNEY TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE
    Jeon, Jin Seok
    Lee, Haekyung
    Kim, Hyoungnae
    Kwon, Soon Hyo
    Noh, Hyunjin
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I1236 - I1236
  • [48] Pre-emptive Allogeneic Hematopoietic Stem Cell Transplantation in Ataxia Telangiectasia
    Bakhtiar, Shahrzad
    Woelke, Sandra
    Huenecke, Sabine
    Kieslich, Matthias
    Taylor, Alexander Malcolm
    Schubert, Ralf
    Zielen, Stefan
    Bader, Peter
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [49] ORAL VALGANCICLOVIR AS EARLY PRE-EMPTIVE TREATMENT FOR CMV REACTIVATION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE IN 45 PATIENTS
    Stanghellini, M. T. Lupo
    Greco, R.
    Generali, T.
    Clerici, D.
    Malato, S.
    Corti, C.
    Carrabba, M. G.
    Lunghi, F.
    Biral, E.
    Peccatori, J.
    Bernardi, M.
    Marcatti, M.
    Fumagalli, L.
    Crippa, F.
    Ciceri, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 184 - 184
  • [50] The rate of cytomegalovirus infection and disease in correlation with the type of haematopoietic stem cell transplantation in the era of pre-emptive antiviral therapy
    Gesundheit, B.
    Or, R.
    Budowski, E.
    Shapira, M.
    Resnick, I.
    Samuel, S.
    Dray, L.
    Kaplan, O.
    Wolf, D.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S244 - S245
12345